Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Flu Speed Ahead in Vaccines Market

This article was originally published in RPM Report

Executive Summary

Large investments by GlaxoSmithKline and Novartis in the US flu vaccine business highlight a rush back into the business. Government subsidies, technical assistance and market creation are making the flu vaccine field an attractive section of the pharma field again. It has been generally viewed for decades as a risky, difficult buisness with very little growth potential. Now the tables have turned.

You may also be interested in...

FDA Has Full Plate This Fall For Vaccines: More Than H1N1

FDA faces the massive task of facilitaing the development and distribution of H1N1 vaccine in the autumn of 2009, but the agency also has some important pending applications for other vaccines in the same timeframe: Prevnar-13, Cervarix, and Gardasil for boys. Wall Street is not showing much excitement about the upcoming decisions. The applicatins could present some pleasant surprises and positive events for the sponsors.

Halo Effect: Pandemic Response, Vaccines and Public Health

Can the vaccine industry ride its effort to protect the public from H1N1 flu virus to an elevated reputation with the public? And will reputation permit the vaccine segmetn to continue to bring out new premium-priced products supported by larger governemnt purchase programs around the world? Those are the type of "halo effect" questions being raised be the financial community in advance of the big swine flu response of 2009-2010.

Novartis Bets Big on Meningitis:Wall Street Awaits Blockbuster Vaccine Franchise

Two years after shaking up the vaccine field with its big entry-acquisition of Chiron, Novartis AG has identified a make-or-break pair of projects in the meningitis area. The meningitis vaccines will determine whether the Novartis bet on vaccines will turn into a smart long-term diversification or a low-return move into an unfamiliar and unfriendly segment of health care.

Related Content


Related Companies

Related Deals

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts